PRIMER: Current clawback mechanism jeopardizes patients’ access to drugs produced in Romania

Georgiana Bendre 21/07/2017 | 16:19

The clawback tax, applied to the manufacturers of pharmaceuticals from Romania, doubled in the last 2 years and represents a double taxation system that jeopardizes patients’ access to drugs produced in Romania and the future of an economy with added value that should become of strategic importance for Romania, says the Union of Industrial Producers of Drugs from Romania (PRIMER).

PRIMER asks the authorities to end this double taxation system.

“PRIMER warns that the payment obligation of clawback type, that actually hides a tax on turnover of drugs manufacturing units increased from 12.3 percent in the third quarter of 2015 to 19.8 percent in the first quarter of 2017 and it’s estimated to grow up to 26 percent in the third quarter of 2017,” says PRIMER.

Dragos Damian, the executive director of the Union, said: „Over 1,500 drugs manufactured in Romania cost in their majority less than RON 25 in pharmacy or hospital. They are all absolutely essential to ensure a wide and immediate access of patients to high quality and efficient treatments,” said Damian.

PRIMER believes that if the drugs that cost less than RON 25 are not exempted from the clawback tax, starting July 1, the patients’ access to cheap drugs will be harder, more than it is now and the competitiveness of drugs producers from Romania will suffer.

BR Magazine | Latest Issue

Download PDF or read online: July August 2022 Issue | Business Review Magazine

The June 2022 issue of Business Review Magazine is now available in digital format, featuring the main cover story titled “Companies Embracing Sustainability For A Better Future” Read it online
Georgiana Bendre | 02/08/2022 | 10:15

You will receive a download link for the latest issue of Business Review Magazine in PDF format, based on the completion of the form below.

I agree with the Privacy policy of business-review.eu
I agree with the storage and handling of my data by business-review.eu

Close ×

We use cookies for keeping our website reliable and secure, personalising content and ads, providing social media features and to analyse how our website is used.

Accept & continue